---
schema_version: "secwatch.filing_event.v1"
accession: "0001055726-26-000024"
form_type: "8-K"
ticker: "INO"
cik: "0001055726"
company_name: "INOVIO PHARMACEUTICALS, INC."
filed_at: "2026-08-12T20:07:49+00:00"
generated_at: "2026-08-12T20:09:27.368788+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# INOVIO reports Q2 2026 net loss of $6.0M; INO-3107 PDUFA on Oct 30, 2026

## Summary
- Net loss of $6.0M ($0.07/share) vs $23.5M ($0.61) in Q2 2025; includes $13.9M non-cash warrant gain.
- Cash and investments $36.7M at June 30, 2026, plus $18.3M from July offering; runway into late Q1 2027.
- FDA review of INO-3107 BLA continues; PDUFA target action date October 30, 2026; commercial launch prep ongoing.
- ApolloBio reported positive Phase 3 topline for VGX-3100 in China for cervical dysplasia.
- Operating expenses fell to $18.6M from $23.1M YoY; R&D down to $10.8M.

## SEC filing metadata
- accession: 0001055726-26-000024
- form_type: 8-K
- ticker: INO
- cik: 0001055726
- company_name: INOVIO PHARMACEUTICALS, INC.
- filed_at: 2026-08-12T20:07:49+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1055726/000105572626000024/0001055726-26-000024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1055726/000105572626000024/ino-20260812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001055726-26-000024
- JSON: https://secwatch.observer/filing/0001055726-26-000024.json
- Plain text: https://secwatch.observer/filing/0001055726-26-000024.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.